Bayer Group
Research at Bayer
As a research-based company, the Bayer Group firmly believes in innovation as a key driver for future growth. We have the necessary resources in place to realize further growth opportunities for the future through research and development activities. In 2007 we invested a total of €2,578 million in research and development, compared with €2,297 million in the previous year. It is particularly important for us to develop new products that strengthen our core businesses while at the same time continuously optimizing our product portfolio and our manufacturing processes. Our research activities are closely aligned to the requirements of our markets, with customer needs and technological advances presenting opportunities for future innovation. With innovation projects in particular, our own research and development activities are supplemented by our international network of collaborations with leading universities, public-sector research institutes and partner companies. Through this pooling of expertise, we aim to rapidly translate new ideas into successful products.
Research in the three subgroups
Of the Group’s entire R&D expenditures, Bayer HealthCare accounted for 66 percent, Bayer CropScience for 25 percent and Bayer MaterialScience for 8 percent.
Research Spending
Research and Development Expenses 2007
|
Research and Development Expenses 2007
|


Investor Relations
Bookmark this page
E-mail this page
